Skip to main content
Fig. 2 | European Journal of Medical Research

Fig. 2

From: Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study

Fig. 2

Hepcidin levels (A) and mean change from baseline by treatment (roxadustat versus ESAs) at week 8 and week 24 (B). sTFR levels (C) and mean change from baseline by treatment (roxadustat versus ESAs) at week 8 and week 24 (D). sTFR denotes serum soluble transferrin receptor. *Significant differences between groups (P < 0.05). **Significant differences between groups (P < 0.01)

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us